Composite Measures of Disease Activity in Psoriatic Arthritis: Comparative Instrument Performance Based on the Efficacy of Guselkumab in an Interventional Phase II Trial

OBJECTIVE: To assess performance of psoriatic arthritis (PsA) composite indices and evaluate guselkumab’s effect on achieving low disease activity or remission. METHODS: In this phase II trial, patients with active PsA (≥3 tender and ≥3 swollen joints, C‐reactive protein level ≥0.3 mg/dl, ≥3% body s...

Descripción completa

Detalles Bibliográficos
Autores principales: Helliwell, Philip S., Deodhar, Atul, Gottlieb, Alice B., Boehncke, Wolf-Henning, Xu, Xie L., Xu, Stephen, Wang, Yuhua, Hsia, Elizabeth C., Gladman, Dafna D., Ritchlin, Christopher T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Psoriatic Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7702129/
https://www.ncbi.nlm.nih.gov/pubmed/31421033
http://dx.doi.org/10.1002/acr.24046

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7702129/
https://www.ncbi.nlm.nih.gov/pubmed/31421033
http://dx.doi.org/10.1002/acr.24046

Ejemplares similares